Phase 1 Mesothelioma Trial, Recruiting NCT06566079 Sponsor: InSilico Medicine Hong Kong Limited Condition: Mesothelioma
Back to Mesothelioma

Phase 1 Mesothelioma Trial, Recruiting

NCT06566079
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years old or older
  • You have been diagnosed with advanced or spreading malignant mesothelioma or another solid tumour that cannot be surgically removed, and standard treatments have not worked or no standard treatment is available
  • If you have mesothelioma, you must have previously received both immunotherapy (immune checkpoint therapy) and platinum-based chemotherapy
  • If you have a solid tumour other than mesothelioma and are joining the second part of the trial, your genetic test results must show a specific change in a cell signalling pathway called the Hippo pathway
  • You have at least one tumour that can be measured or evaluated on scans
  • You are generally well enough to carry out light activity and care for yourself (confirm with trial site)
  • Your doctor expects you to live for at least 12 weeks
  • Your kidneys, liver, and other organs are working well enough, based on recent blood tests taken within 7 days before starting treatment
  • You are able to understand and sign a consent form and follow the study rules

Who may not be able to join:

  • You have previously received a type of drug called a TEAD inhibitor
  • You have taken part in another treatment clinical trial within the past 28 days (or within a certain time based on the drug used — confirm with trial site)
  • You have received any cancer treatment within the past 28 days (or within a certain time based on the drug used — confirm with trial site)
  • You have an active brain or spinal cord tumour, or brain tumours that have not yet been treated
  • You have a severe or poorly controlled serious illness, as judged by your doctor
  • You are unable or unwilling to swallow tablets or capsules, or you have a stomach or bowel condition that could affect how the drug is absorbed
  • You have a significant past or current medical condition, surgery, or abnormal test result that your doctor believes could put you at risk or affect how the study drug works in your body
  • You are currently taking certain medications that interact with how the study drug is processed in the body and cannot stop taking them before the trial begins (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86 021-50831718

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
InSilico Medicine Hong Kong Limited
Registry
ClinicalTrials.gov
Start date
27 December 2024
Est. completion
31 August 2027

Where this trial is recruiting

🇨🇳 China 🇺🇸 United States

Primary endpoints

Incidence of dose-limiting toxicity (DLT).; Incidence and severity of adverse events (AEs); Incidence of clinically significant abnormalities in laboratory values, vital signs, physical examination, and electrocardiogram (ECG) measurements.; Recommended Phase 2 Dose (RP2D)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov